Clinical trials: Tyrosine Kinase Inhibitor
Gastrointestinal Stromal Tumors
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Activating mutations of the kinases CKIT or PDGFRA can be detected in 90% of cases by DNA sequence analysis of a pathological specimen.
- Trial name
- NCT01462994
- Testing
- Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Technical University of Munich
Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase II trial evaluates how effective 560 mg of ibrutinib taken by mouth daily is in the treatment of classical Hodgkin lymphoma which recurs or does not respond to initial treatment.
- Conditions
- Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
- Trial name
- NCT02824029
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non Small Cell Lung Cancer
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase. For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment…
- Trial name
- NCT04622072
- Testing
- XZP-5809-TT1 Tablet
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Pulmonary Arterial Hypertension
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
- Trial name
- NCT00477269
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States, Austria and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of…
- Trial name
- NCT02122913
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bayer
Ovarian Cancer
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
- Trial name
- NCT00866697
- Testing
- Pazopanib
- Where
- 318 sites in United States, Australia and 15 more
- Volunteers
- 940 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.
- Trial name
- NCT01449162
- Testing
- Masitinib
- Where
- 8 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 420 people
- Sponsor
- AB Science
Waldenstrom Macroglobulinemia
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations…
- Trial name
- NCT05640102
- Testing
- Zanubrutinib
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 111 people
- Sponsor
- BeiGene
Bioavailability, B-cell Lymphoid Cancer
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
This study will be a 2-part, open-label, single-center relative bioavailability, PPI effect, food-effect and particle size effect randomized crossover study of acalabrutinib tablets in healthy subjects (males or females).
- Trial name
- NCT04488016
- Testing
- Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Intrahepatic Cholangiocarcinoma (Icc)
A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
The study aims to evaluate the efficacy and safety of Apatinib and Adebrelimab in Combination With chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC)
- Trial name
- ACADEMY (NCT06925516)
- Testing
- Apatinib and Adebrelimab in Combination With chemotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-Hodgkins Lymphoma, Multiple Myeloma
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.
- Conditions
- Non-Hodgkins Lymphoma, Multiple Myeloma, B-All
- Trial name
- NCT02328014
- Testing
- Acalabrutinib, ACP-319
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Acerta Pharma BV
Metastatic Gastrointestinal Stromal Tumor
Ph II CABOGIST in GIST
The study is a multi-center, multi-national, open label, single arm Phase II study of single-agent cabozantinib. The objective of the study is to assess the safety and activity of cabozantinib in patients with metastatic GIST who…
- Trial name
- NCT02216578
- Testing
- cabozantinib
- Where
- 11 sites in Belgium, Czechia and 4 more
- Volunteers
- 51 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Food Allergy, Food Allergy Peanut
Preventing Anaphylaxis With Acalabrutinib
Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis.
- Trial name
- NCT05038904
- Testing
- Acalabrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Metastatic Castrate Resistant Prostate Cancer
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Study of masitinib plus docetaxel as first-line chemotherapy in men with metastatic castration-resistant prostate cancer.
- Trial name
- NCT03761225
- Testing
- Masitinib, Docetaxel, Prednisone
- Where
- 9 sites in Canada, France and 4 more
- Volunteers
- 714 people
- Sponsor
- AB Science
Depression
Examination of a Soy-Based Supplement for Major Depression
The purpose of this study is to find out if the soy-based dietary supplement Novasoy (Registered Trademark) is effective for the short-term treatment of clinical depression.
- Trial name
- NCT00042380
- Testing
- Novasoy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Mental Health (NIMH)
Non Small Cell Lung Cancer
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
Lung cancer is the most common neoplastic disease globally, with over 2 million new cases annually, accounting for 11.6% of all cancer diagnoses. It remains the leading cause of cancer-related deaths.
- Trial name
- METLUNG (NCT05445791)
- Testing
- Metformin Hydrochloride
- Where
- Mexico
- Volunteers
- 312 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
This is a prospective, phase 2, multicenter, open-label, single-arm study. Primary objective is to assess the efficacy of loncastuximab tesirine given as consolidation therapy after salvage immunochemotherapy in BTKi (Bruton…
- Trial name
- FIL_COLUMN (NCT05249959)
- Testing
- Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
- Where
- 19 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Efficacy, Toxicity
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy.
- Trial name
- NCT03491371
- Testing
- Methylsulfonic apatinib
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Peking University People's Hospital
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center